<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Brawn Biotech Ltd has filed a confirmation with BSE stating that it does not fall under the 'Large Corporate' category as of 31st March 2025, in line with SEBI circular dated 26 November 2018. Under this SEBI framework, companies classified as Large Corporates are required to raise at least 25% of their incremental borrowings through debt securities. By confirming it does not meet this threshold, Brawn Biotech is exempt from the related debt-security issuance obligations. The disclosure was signed by Priyanka Sharma, Company Secretary and Compliance Officer, on 30 April 2025.
This is a routine compliance filing and has no direct impact on shareholders or the stock price. It simply indicates that Brawn Biotech is below the size threshold that would mandate a minimum share of bond/debt-market funding, leaving the company with no obligation to tap the debt securities market for now.